Literature DB >> 3153271

Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.

K Tamanaha1, R H Mak, S P Rigden, C Turner, K M Start, G B Haycock, C Chantler.   

Abstract

Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years. Both aluminum hydroxide and calcium carbonate were used initially, but almost all patients were taking calcium carbonate towards the end of the period. Serum immunoreactive parathyroid hormone concentrations were significantly decreased and were within the normal range after 1 year and remained normal during treatment. There was no significant change in renal function over the same treatment period. We conclude that calcium carbonate should be used as the phosphate binder of choice in the long-term suppression of hyperphosphatemia and hyperparathyroidism in uremic children.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3153271     DOI: 10.1007/bf00849285

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

2.  How important is phosphate in the pathogenesis of renal osteodystrophy?

Authors:  E Slatopolsky; W E Rutherford; K Hruska; K Martin; S Klahr
Journal:  Arch Intern Med       Date:  1978-05-15

3.  The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure.

Authors:  E M Clarkson; S J McDonald; H E De Wardener
Journal:  Clin Sci       Date:  1966-06       Impact factor: 6.124

4.  Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.

Authors:  L Tougaard; E Sorensen; J Brochner-Mortensen; M S Christensen; P Rodbro; A W Sorensen
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

5.  Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.

Authors:  P Moriniere; A Roussel; Y Tahiri; J F de Fremont; G Maurel; M C Jaudon; J Gueris; A Fournier
Journal:  Proc Eur Dial Transplant Assoc       Date:  1983

6.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Aluminum loading in children with chronic renal failure.

Authors:  A B Sedman; N L Miller; B A Warady; G M Lum; A C Alfrey
Journal:  Kidney Int       Date:  1984-08       Impact factor: 10.612

8.  Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.

Authors:  C Christiansen; P Rødbro; M S Christensen; B Hartnack; I Transbøl
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

9.  On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.

Authors:  E Slatopolsky; S Caglar; J P Pennell; D D Taggart; J M Canterbury; E Reiss; N S Bricker
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

10.  Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure.

Authors:  J C Chan; M B Kodroff; D M Landwehr
Journal:  Pediatrics       Date:  1981-10       Impact factor: 7.124

View more
  7 in total

1.  The treatment of renal osteodystrophy.

Authors:  S P Rigden
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Recent developments in vitamin D metabolism and its clinical application for renal disease.

Authors:  R W Chesney
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

4.  Treatment of severe hypercalcemia with peritoneal dialysis in an infant with end-stage renal disease.

Authors:  U Querfeld; I B Salusky; R N Fine
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

5.  Clinical quiz. Aluminum toxicity.

Authors:  R Baliga; R W Chesney; F G Boineau; J E Lewy
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

6.  Chronic renal failure and growth.

Authors:  L Rees; S P Rigden; G M Ward
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

7.  Insulin and growth in chronic renal failure.

Authors:  R H Mak; G B Haycock; C Chantler
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.